Sort   by:  
 Page size 
MetabolomicsSearching for Drug Synergy Against Cancer Through Polyamine Metabolism Impairment: Insight Into the Metabolic Effect of Indomethacin on Lung Cancer Cells
Non-small cell lung cancer (NSCLC) is the most lethal and prevalent type of lung cancer. In almost all types of cancer, the levels of polyamines (putrescine, spermidine, and spermine) are increased, playing a pivotal role in tumor proliferation. Indomethacin, a non-steroidal anti-inflammatory drug, ...
2021-02-08 | MTBLS873 | MetaboLights
MetabolomicsConsistency across multi-omics layers in a drug-perturbed gut microbial community
Multi-omics analyses are increasingly employed in microbiome studies to obtain a holistic view of molecular changes occurring within microbial communities exposed to different conditions. However, it is not always clear to what extent each omics data type contributes to our understanding of the comm...
2022-12-08 | MTBLS3129 | MetaboLights
MetabolomicsAdjunctive ibuprofen in pre-extensively drug-resistant and extensively drug-resistant tuberculosis: a Phase IIA open-label pilot clinical trial

Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) aim to limit tissue damage, shorten treatment, and improve outcomes by modulating immune responses. We evaluated the safety and potential efficacy of adjunctive ibuprofen an inexpens...

2026-05-28 | MTBLS13376 | MetaboLights
MetabolomicsEffect of Pro-longevity drugs on Lipid profile, link between lipid signalling and longevity
We report the effect of four lifespan modifying drugs and of combinations of these drugs on lipid profile in Caenorhabditis elegans. We investigated drug-drug interactions and identified beneficial drug interactions between drugs selected to target synergistic longevity mechanisms and pathways. We e...
2018-06-08 | MTBLS648 | MetaboLights
MetabolomicsRabbit plasma metabolomic analysis of Nitroproston: a multi target natural prostaglandin based-drug (Untargeted study)
INTRODUCTION: Nitroproston® is a novel multi-target drug bearing natural prostaglandin E2 (PGE2) and nitric oxide (NO)-donating fragments for treatment of inflammatory and obstructive diseases (i.e. asthma and obstructive bronchitis). OBJECTIVES: To investigate the effects of Nitroproston® adm...
2019-08-27 | MTBLS727 | MetaboLights
Metabolomics1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug
1H high resolution magic angle spinning (HR-MAS) NMR spectroscopy was applied in combination with multivariate statistical analyses to study the metabolic response of whole cells to the treatment with a hexacationic ruthenium metallaprism [1]6+ as potential anticancer drug. Human ovarian cancer cell...
2015-01-16 | MTBLS156 | MetaboLights
MetabolomicsProtective Effects of Cordycepin against Oxaliplatin-Associated Drug-Induced Fatty Liver Disease and Preliminary Mechanistic Insights

Oxaliplatin (OXA) is a chemotherapeutic agent used to treat multiple malignancies. Although it predominantly causes hepatic sinusoidal obstruction syndrome, it also induces drug-induced fatty liver disease (DIFLD) via lipid metabolic dysregulation and oxidative stress, which persists post-cessati...

2025-09-04 | MTBLS12938 | MetaboLights
MetabolomicsAnti-anemia drug FG4592 retards the AKI to CKD transition by improving vascular regeneration and anti-oxidative capability (day 10)

Acute kidney injury (AKI) is a known risk factor for the development of chronic kidney disease (CKD), with no satisfactory strategy to prevent the progression of AKI to CKD. Damage to the renal vascular system and subsequent hypoxia are common contributors to both AKI and CKD. Hypoxia inducible f...

2021-07-22 | MTBLS3056 | MetaboLights
MetabolomicsAnti-anemia drug FG4592 retards the AKI to CKD transition by improving vascular regeneration and anti-oxidative capability (day 21)

Acute kidney injury (AKI) is a known risk factor for the development of chronic kidney disease (CKD), with no satisfactory strategy to prevent the progression of AKI to CKD. Damage to the renal vascular system and subsequent hypoxia are common contributors to both AKI and CKD. Hypoxia inducible f...

2021-07-22 | MTBLS3003 | MetaboLights
MetabolomicsMetabolomics reveals molecular signatures for psoriasis biomarkers and drug targets discovery
Psoriasis is a chronic skin disease that affects multiple systems and can be influenced by immunological, environmental, and genetic factors. The discovery of plasma biomarkers of psoriasis and the regulation of metabolic pathways helps us understand psoriasis and may assist clinicians in the diagno...
2024-09-26 | MTBLS5185 | MetaboLights
Sort   by:  
 Page size